TMCI Investors are Urged to Contact Robbins LLP for Information About the Treace Medical Concepts, Inc. Class Action Lawsuit
SAN DIEGO, CA - May 3, 2025 ( NEWMEDIAWIRE ) - Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that Treace Medical Concepts, Inc. (TMCI) Misled Investors Regarding Demand for its Primary Product
According to the complaint, during the class period, defendants failed to disclose that (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System, and (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function). Plaintiff alleges that when the truth was revealed, the price of Treace Medical's stock fell nearly 63%, to close at $4.17 per share on May 8, 2024.
What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 10, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Treace Medical Concepts, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
[email protected]
(800) 350-6003
www.robbinsllp.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Can Investing $10,000 in Quantum Computing (QUBT) Stock Turn Into $1 Million by 2035?
Quantum Computing would need to deliver a CAGR of roughly 58.49% to turn $10,000 into $1 million by 2035. Explosive growth in the photonic integrated circuit market could help the company achieve this goal. However, the probability that Quantum Computing will be a millionaire-maker in 10 years is still low. 10 stocks we like better than Quantum Computing › Quantum Computing (NASDAQ: QUBT) is an up-and-coming pioneer in the red-hot field of quantum computing. Could investing $10,000 in this stock turn into $1 million by 2035? It's possible, but the odds are stacked against it. That said, I think there is a viable path for Quantum Computing to make you a millionaire over the next 10 years. Here's what would be required. Quantum Computing's market cap currently hovers around $2.66 billion. Its share price was $18.88 at the market close on June 20, 2025. An investment of $10,000 would buy 529 shares at that price, with $12.48 left over. The company's share price would need to grow 100x to $1,888 for a $10,000 initial investment (assuming you didn't buy any fractional shares) to be worth $1 million in a decade. That reflects a compound annual growth rate (CAGR) of roughly 58.49%. Quantum Computing has certainly demonstrated that it can deliver a much greater annual return than that over the short term. Over the last 12 months, the stock has skyrocketed by more than 3,000%. Sustaining a CAGR of 58.49% over 10 years is a daunting task, but it's not impossible. For example, a $10,000 investment in Nvidia in 2015 would be worth over $2.6 million today. Of course, you would have had to resist the temptation to sell during the GPU stock's huge swings up and down during that period. Now for a more difficult question: How could Quantum Computing stock achieve a CAGR of 58.49% over the next 10 years? To answer this question, we need to understand the company's business. Quantum Computing uses integrated photonics (computing with particles of light) and nonlinear quantum optics to develop quantum computers. The company believes its approach to quantum computing is superior to rivals' methods that use superconducting, trapped-ion, and annealing architectures. Photons' advantages include lower energy consumption, faster processing, and scalability. The photonic integrated circuit market size in 2024 was around $15 billion. Over the next five years, this market is projected to expand by a CAGR of 20.5% to $38.4 billion. While that is an impressive growth rate, it isn't enough to propel Quantum Computing stock 100x higher. But Quantum Computing could grow significantly faster than the overall photonic integrated circuit market. The company's thin film lithium niobate wafers, which it believes will be "the silicon of the future," could make it possible. Also, the photonic integrated circuit market's growth could accelerate beyond 2029. I could envision this occurring if the adoption of the technology in areas such as artificial intelligence (AI), autonomous vehicles, and high-performance computing takes off in a huge way. It's quite possible that investing $10,000 in Quantum Computing stock could make you a millionaire over the next 10 years. But how probable is this scenario? The odds aren't great. For one thing, Quantum Computing's photonics technology might be surpassed by approaches that prove to be even better. Many of the companies investing heavily in developing quantum computers have deep pockets, including Google parent Alphabet, Amazon, IBM, Microsoft, and Nvidia. Other rising stars in the quantum computing industry, such as IonQ, D-Wave Quantum, and Rigetti Computing, could potentially be bigger winners than Quantum Computing. Perhaps progress in advancing quantum computing technology won't be fast enough to support the market growth required for Quantum Computing to be a millionaire-maker. I suspect that won't be the case, but I wouldn't rule it out. The good news for investors, though, is that Quantum Computing doesn't have to turn an initial $10,000 into $1 million by 2035 to still deliver exceptional returns. Before you buy stock in Quantum Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Quantum Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights has positions in Alphabet, Amazon, and Microsoft. The Motley Fool has positions in and recommends Alphabet, Amazon, International Business Machines, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Can Investing $10,000 in Quantum Computing (QUBT) Stock Turn Into $1 Million by 2035? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
3 of Wall Street's Favorite Stocks Playing with Fire
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it's worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover. Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. That said, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals. Consensus Price Target: $9.28 (89.8% implied return) Established in 1996, Pangaea Logistics (NASDAQ:PANL) specializes in global logistics and transportation services, focusing on the shipment of dry bulk cargoes. Why Should You Dump PANL? Customers postponed purchases of its products and services this cycle as its revenue declined by 5.5% annually over the last two years Earnings per share have contracted by 33.9% annually over the last three years, a headwind for returns as stock prices often echo long-term EPS performance Free cash flow margin dropped by 9.1 percentage points over the last five years, implying the company became more capital intensive as competition picked up At $4.89 per share, Pangaea trades at 8.9x forward P/E. Read our free research report to see why you should think twice about including PANL in your portfolio, it's free. Consensus Price Target: $2.53 (239% implied return) Founded by two brothers, Purple (NASDAQ:PRPL) creates sleep and home comfort products such as mattresses, pillows, and bedding accessories. Why Are We Out on PRPL? Products and services aren't resonating with the market as its revenue declined by 6.3% annually over the last two years Eroding returns on capital from an already low base indicate that management's recent investments are destroying value Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders Purple is trading at $0.75 per share, or 24.5x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why PRPL doesn't pass our bar. Consensus Price Target: $31.50 (50.6% implied return) Originally founded in 1983 as the first private prison company in the United States, CoreCivic (NYSE:CXW) operates correctional facilities, detention centers, and residential reentry programs for government agencies across the United States. Why Do We Avoid CXW? Sluggish trends in its average available beds suggest customers aren't adopting its solutions as quickly as the company hoped Earnings per share have dipped by 5.6% annually over the past three years, which is concerning because stock prices follow EPS over the long term Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 10.2 percentage points CoreCivic's stock price of $20.91 implies a valuation ratio of 23x forward P/E. To fully understand why you should be careful with CXW, check out our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
Business Wire
2 hours ago
- Business Wire
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
BOSTON & OSAKA, Japan--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other B cell-mediated diseases. Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex's clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications. 'Ono is a proven leader in Japan and South Korea, bringing established local relationships, infrastructure and nephrology expertise that make them a perfect partner for Vertex as we look to deliver povetacicept to the thousands of potential patients in these countries,' said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. 'We are very pleased to partner with Ono and look forward to close collaboration as we continue to advance this potentially best-in-class treatment for IgAN, pMN and other serious B cell-mediated diseases.' 'Vertex has a strong track record of developing innovative therapies for serious diseases. Through this strategic partnership, we can strengthen our late-stage pipeline in the immunology field, which is a key focus area for Ono,' said Toichi Takino, Representative Director, President and Chief Operating Officer of Ono. 'We look forward to collaborating with Vertex to provide this new therapeutic option for patients with IgAN and other autoimmune diseases in Japan and South Korea, and to maximize the value of this treatment.' About Povetacicept Povetacicept is a recombinant fusion protein therapeutic and a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation and/or survival of B cells, T cells and innate immune cells. Based upon an engineered TACI (transmembrane activator and calcium modulator ligand interactor) domain, povetacicept has higher binding affinity and greater potency in preclinical studies versus other inhibitors of BAFF and/or APRIL alone and has demonstrated potential best-in-class efficacy in a clinical trial in patients with IgA nephropathy and primary membranous nephropathy. Povetacicept is also in development for multiple serious B cell-mediated diseases including other autoimmune kidney diseases and autoimmune cytopenias. About IgA Nephropathy (IgAN) IgAN is a serious, progressive, life-threatening, B cell-mediated chronic kidney disease that is the most common cause of primary (idiopathic) glomerulonephritis, affecting approximately 300,000 people in the United States and Europe. It is estimated that there are approximately 33,000 diagnosed patients in Japan. IgAN results from deposition of circulating immune complexes consisting of immunoglobulins and galactose-deficient immunoglobulin A (Gd-IgA1) in the renal glomerular mesangium, triggering kidney injury and fibrosis. Up to 72% of adult IgAN patients progress to end-stage renal disease within 20 years. There are no approved therapies that specifically target the underlying cause of IgAN. About Primary Membranous Nephropathy (pMN) Primary membranous nephropathy is a serious, progressive, life-threatening B cell-mediated chronic kidney disease affecting people worldwide, with approximately 150,000 people diagnosed in the U.S. and Europe. It is estimated that there are approximately 6,000 diagnosed patients with pMN in Japan. pMN is a rare glomerular disease that occurs when the body generates an abnormal immune response, including autoantibodies, against proteins that are part of the kidney. Autoantibodies trigger damage and inflammation, especially within the glomeruli (the parts of the kidney that filter blood), impairing the kidneys' ability to properly filter waste and fluid, eventually causing progressive loss of kidney function. There are no approved therapies that specifically target the underlying cause of pMN. About RAINIER RAINIER is a global Phase 3 pivotal trial of povetacicept 80 mg vs. placebo on top of standard of care in approximately 480 people with IgAN. The study is designed to have a pre-planned interim analysis evaluating urine protein to creatinine ratio (UPCR) for the povetacicept arm versus placebo after a certain number of patients reach 36 weeks of treatment. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval in the U.S. Final analysis will occur at two years of treatment, with a primary endpoint of total eGFR slope through Week 104. The Phase 3 clinical trial is underway in multiple regions, including the U.S., EU and Asia. Specifically, Japanese and South Korean regulatory authorities have approved the Clinical Trial Application (CTA) for RAINIER, where the Phase 3 trial is underway. About RUBY-3 RUBY-3 is an ongoing, multiple ascending dose, multi-cohort, open label, Phase 1/2 basket study of povetacicept in autoimmune glomerulonephritis, including IgAN, primary membranous nephropathy, lupus nephritis and ANCA-associated vasculitis with glomerulonephritis where povetacicept is being administered subcutaneously for up to 104 weeks. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. About Ono Pharmaceutical Co., Ltd Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of 'Dedicated to the Fight against Disease and Pain,' Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at Vertex Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Reshma Kewalramani M.D., and Toichi Takino, in this press release, and statements about the terms of and expectations for Vertex's collaboration with Ono, statements about potential benefits and results that may be achieved through the collaboration, statements regarding the future activities of the parties pursuant to the collaboration, including Ono's help to advance clinical trials and Ono's responsibility to obtain marketing authorizations in Japan and South Korea and to commercialize povetacicept in the regions, statements regarding upfront and milestone payments, and potential royalties on future products, and statements about Vertex's plans and expectations for the RAINIER and RUBY-3 clinical trials and potential plans to seek accelerated approval in the U.S. based on interim analysis from the RAINIER trial. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the anticipated benefits and potential of the collaboration between Vertex and Ono may not be achieved on the anticipated timeline, or at all, that data may not support further development of the therapies subject to the collaboration due to safety, efficacy, or other reasons, and other risks listed under the heading 'Risk Factors' in Vertex's annual report filed with the Securities and Exchange Commission (SEC) and available through Vertex's website at and on the SEC's website at You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Ono Forward-Looking Statements In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.
